Lung targeting dual drug delivery system

摘要

The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.

主权项

1. A delivery system comprising a gel microparticle, a plurality of nanoparticles associated with the gel microparticle, and one or more hydrophobic drugs associated with at least one of the nanoparticles, wherein the gel microparticle includes aqueous soluble polymers or copolymers that are gelled by a crosslinking reaction selected from the group consisting of free radical polymerization, mannich reactions, hydrophobic association, metal ion mediated complexation, amide formation reactions, ester formation reactions, and azide alkyne Huisgen cycloaddition, and the nanoparticles include PEG protective coatings.